Parsons not on ONCY board for licensing & biobuck dealsONCY didn't appoint James Parsons to the board to advise on licensing & biobuck deals.
https://www.oncolyticsbiotech.com/press-releases/detail/577/oncolytics-biotech-announces-voting-results-from-the
Furthermore, ONCY has recently begun describing peleareorep as an IMMUNE PLATFORM MOLECULE, which is consistent with the way that the molecular biologic agent works across a broad range of drug classes and indications in the treatment of multiple cancers.